ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to present at Prion 2017 International Conference
TORONTO and CAMBRIDGE, MA, May 25, 2017 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that Neil Cashman, MD, Chief Scientific Officer and Co-Founder will present today at PRION 2017, the International Conference Deciphering Neurodegenerative Disorders in Edinburgh, Scotland.
Dr. Cashman's presentation, entitled Epitope Identification of Toxic Propagating Strains of Aβ Oligomers, describes the use of ProMIS' proprietary discovery engine to identify targets (epitopes) on toxic prion-like forms of Amyloid beta oligomers (AbO), considered a root cause of Alzheimer's disease.
Commenting on the presentation, Dr. Cashman stated, "we have been able to raise antibodies against these epitopes that selectively bind the toxic prion-like forms of Amyloid beta and block their neurotoxicity and propagation. To date, two of these antibodies - PMN310 and PMN350 - each selectively addressing a different target epitope - have been designated as our lead products for development in Alzheimer's disease."
Organizers of the conference anticipate participation of more than 400 academics, strategists, innovators, policy makers and researchers from public and private sector across the international field of Prion research. The 14th annual conference will gather attendees to discuss the latest research being carried out in prion diseases and the broader field of neurodegenerative diseases and to examine the commonalities and differences between these devastating diseases.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at:
SOURCE ProMIS Neurosciences Inc.
For further information: For media inquiries, please contact: Scott Santiamo, RussoPartners/LLC, Scott.Santiamo@russopartnersllc.com, Tel. 718 344-5843; David Schull, RussoPartners/LLC, David.Schull@russopartnersllc.com, Tel. 858 717-2310; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, firstname.lastname@example.org